We presented a Cantech this week - Dans pesentation was well received and Rob Ballard (Pathfinder Asset Management) picked VHI as on of his top picks for 2019! https://t.co/RmjdUorVBi
Congratulations to Dr John Wallace, our chief scientific officer, and his colleagues for their recent paper in the Journal of Biomedical Science, showing a way forward in the treatment of #Crohns disease and ulcerative #colitis https://t.co/mt6gokRcfU $ATBPF $ATE.V
We've received Health Canada's approval for Part 2 of the Phase 2b study for our lead drug. Following successful completion of the Part 1 safety study late last year, Part 2 will focus on efficacy, involving 360 patients across 35 centers https://t.co/4y9TYQYrsZ
$ATBPF $ATE.V